Xarelto Patient Assistance Program
Xarelto (rivaroxaban) is an anticoagulant prescribed to reduce the risk of blood clots in adults. Along with medical monitoring, it works by blocking certain clotting proteins in the blood and belongs to a class of medications called factor Xa inhibitors.
Affording Xarelto becomes difficult when insurance provides inadequate prescription coverage. Patient Assistance Programs (PAPs) exist to address this challenge for eligible individuals. Pharmaceutical companies fund and operate these programs to maintain ongoing medication access for people whose insurance falls short or who lack coverage altogether.
How Prescription Details Affect Xarelto Assistance Eligibility

About the Xarelto Patient Assistance Program
These programs are designed specifically for adults prescribed Xarelto who cannot manage the medication’s cost. Enrollment reduces or eliminates out-of-pocket expenses for qualifying individuals, ensuring uninterrupted access to blood clot prevention.
The application process begins when you gather your healthcare provider’s prescription along with household income records.
Patient Help Network takes responsibility for managing enrollment documentation, obtaining medical verification from your care team, submitting applications to the manufacturer, and tracking approval progress. If approved, you can expect your medication to show up consistently to your front door.
How Xarelto Works
Recognizing how this medication prevents dangerous blood clots helps clarify why consistent access matters. Xarelto contains rivaroxaban, which inhibits factor Xa, a protein essential for blood clot formation. By blocking this protein, the medication reduces the blood’s ability to form clots that could travel to the lungs, brain, or other vital organs.
The medication comes as a tablet taken orally, typically once or twice daily depending on the condition being treated.
Dosing schedules vary based on whether Xarelto is prescribed for atrial fibrillation, deep vein thrombosis, pulmonary embolism, or post-surgical clot prevention.
Side Effects and Safety Information
All anticoagulant medications carry risks that require understanding before treatment begins. The most common side effects may include easy bruising, minor bleeding that takes longer than usual to stop, nosebleeds, bleeding gums when brushing teeth, and heavier menstrual periods. These may appear after starting treatment or following dosage changes. Any unusual or worsening bleeding should be reported to your healthcare provider right away. Serious bleeding represents the most significant risk with Xarelto.
Internal bleeding may manifest through symptoms like unusual headaches, dizziness, weakness, blood in urine or stools, coughing up blood, or vomiting blood or material that looks like coffee grounds. Any signs of serious bleeding require immediate emergency medical attention.
Xarelto carries warnings about spinal or epidural blood clots for people receiving spinal procedures while taking the medication. People scheduled for surgery or dental procedures must inform their healthcare providers about Xarelto use. Stopping the medication without medical guidance increases stroke risk in people with atrial fibrillation.
Step 1 – Submit Application
Provide basic prescription and household information to begin the application process.
Step 2 – Application Review
Information is reviewed and submitted to appropriate Patient Assistance Programs.
Step 3 – Program Decision
Final eligibility decisions are made by each program. Additional steps or renewals may be required.
PHN will contact you within 24 hours to discuss your situation and help identify appropriate next steps for the application process.
How it applies / Eligibility
Manufacturers assess applications against established criteria when determining assistance eligibility. Meeting these baseline requirements strengthens approval likelihood:
- Individuals earning below $40,000 annually
- Two-person households with combined income under $60,000 yearly
- Families of three or more with total household income below $100,000 annually
- Current Xarelto prescription from a licensed healthcare provider
- Documentation confirming U.S. citizenship or legal residency
- Prescription coverage that is limited, inadequate, or absent
Financial status represents one consideration among multiple factors manufacturers evaluate.
Different programs emphasize varying criteria during their review process, assessing each submission individually. Program capacity affects acceptance, with some manufacturers operating waitlists during high-demand periods. Early application submission improves the likelihood of securing available program slots.
Frequently asked questions (FAQ`s)
Manufacturers provide explanations when denying applications. Typical reasons involve income exceeding established thresholds, existing coverage deemed sufficient, or incomplete required documentation. Reapplication becomes possible when financial circumstances change or when you can supply additional paperwork addressing the denial basis.
Continued enrollment requires annual eligibility reconfirmation. This process involves submitting current income verification and obtaining prescription renewal confirmation from your healthcare provider. Failing to complete renewal by the deadline results in program removal and necessitates full reapplication for continued assistance.
Applications require a valid Xarelto prescription from your licensed healthcare provider, documentation establishing total annual household income, proof confirming U.S. citizenship or legal resident status, and information detailing current prescription drug coverage or lack thereof.
Patient Help Network oversees the complete application process. We confirm you satisfy basic eligibility standards, compile all required documentation, communicate with your healthcare provider for necessary information, and submit thoroughly completed applications to manufacturers.
The FDA approved generic rivaroxaban tablets in 2025. However, the medication maintains patent protection preventing generic manufacturing at this time.
Review duration varies depending on the volume of applications manufacturers receive and their current processing schedules. Patient Help Network maintains contact with manufacturers regarding submitted applications and delivers status updates as the review advances.
Manufacturers retain authority to modify program parameters, including income thresholds, coverage adequacy determinations, and other qualification criteria. Patient Help Network monitors these programs for requirement modifications and alerts applicants when changes occur affecting their eligibility standing.